Riluzole
 OpenBabel02212023462D

 15 16  0  0  0  0  0  0  0  0999 V2000
   -1.4534   -0.6979    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6284   -0.6979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1435   -1.3654    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6411   -1.1104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6411   -0.2854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1435   -0.0305    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.3556    0.1271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0701   -0.2854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7845    0.1271    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.7845    0.9521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7845    1.7771    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.6095    0.9521    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.9595    0.9521    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.0701   -1.1104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3556   -1.5229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  2  6  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4 15  1  0  0  0  0
  5  6  1  0  0  0  0
  5  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  8 14  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 10 12  1  0  0  0  0
 10 13  1  0  0  0  0
 14 15  2  0  0  0  0
M  END
>  <CdId>
274

>  <Mol Weight>
234.198

>  <Formula>
C8H5F3N2OS

>  <ID>
T0349

>  <Name>
Riluzole

>  <Synonyms>
RP-54274;PK 26124

>  <CAS>
1744-22-5

>  <Approved status>
FDA

>  <Disease>
Nervous system

>  <Indication>
Amyotrophic Lateral Sclerosis

>  <Pathways>
Membrane transporter/Ion channel; Neuroscience

>  <Target>
NMDAR antagonist; Sodium Channel inhibitor

>  <Receptor>
NMDA receptor; Sodium Channel

$$$$
